NASDAQ · LIFE
Healthcare · Biotechnology
$38.55
Down-$0.12 (-0.31%)
Updated Sep 17, 2026, 6:02 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LIFE closed at $38.55 after 20 trading sessions, up 17.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $39.70 | $40.80 | $38.20 | $38.55 | 2.91M |
| Sep 15, 2026 | $37.93 | $40.455 | $37.00 | $40.28 | 2.26M |
| Sep 14, 2026 | $39.63 | $40.76 | $38.36 | $39.36 | 983.74K |
| Sep 11, 2026 | $38.69 | $40.92 | $38.69 | $40.25 | 995.6K |
| Sep 10, 2026 | $38.61 | $40.00 | $37.76 | $38.85 | 874.97K |
| Sep 9, 2026 | $41.42 | $42.21 | $38.91 | $39.72 | 2.26M |
| Sep 8, 2026 | $39.76 | $42.55 | $39.665 | $42.02 | 1.47M |
| Sep 4, 2026 | $37.76 | $39.89 | $36.5801 | $39.85 | 1.04M |
| Sep 3, 2026 | $37.48 | $38.85 | $37.415 | $37.71 | 722.14K |
| Sep 2, 2026 | $35.66 | $37.28 | $34.85 | $36.80 | 1.22M |
| Sep 1, 2026 | $35.06 | $36.01 | $34.83 | $35.00 | 1.07M |
| Aug 31, 2026 | $38.64 | $38.64 | $35.77 | $36.33 | 1.13M |
| Aug 28, 2026 | $39.60 | $40.19 | $37.73 | $38.64 | 1.09M |
| Aug 27, 2026 | $39.40 | $40.93 | $38.72 | $39.44 | 987.12K |
| Aug 26, 2026 | $38.24 | $40.9699 | $38.00 | $39.11 | 1.61M |
| Aug 25, 2026 | $36.96 | $38.94 | $36.62 | $38.56 | 2.02M |
| Aug 24, 2026 | $33.05 | $37.17 | $32.00 | $36.72 | 2.62M |
| Aug 21, 2026 | $33.90 | $34.49 | $32.51 | $34.16 | 850.09K |
| Aug 20, 2026 | $32.86 | $34.225 | $31.845 | $33.52 | 1.53M |
| Aug 19, 2026 | $34.37 | $34.37 | $32.2325 | $32.85 | 1.04M |
The latest Smart Investors Daily articles mentioning LIFE.
LIFE research
Company profile and research snapshot.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Citigroup | Buy | — |
| Aug 4, 2026 | Citizens | Market Outperform | — |
| Aug 4, 2026 | Baird | Outperform | — |
| Aug 4, 2026 | Barclays | Overweight | — |
| Jul 13, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Finnhub · May 15, 2026
AUSTIN, Texas, May 15, 2026 -- Ethos , a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer,...
Benzinga · May 13, 2026
Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the
Finnhub · May 13, 2026
Ethos , a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to...
Benzinga · May 8, 2026
Barclays analyst Ross Sandler maintains Ethos Technologies (NASDAQ:LIFE) with a Overweight and raises the price target from $20 to $27.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LIFE.
